Top story

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 31, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

Read full story

Novavax's Nuvaxovid 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Drugs.com - New Drug Approvals

Wed, 27 Aug 2025

Gadoquatrane New Drug Application Accepted for Review by U.S. FDA

Drugs.com - New Drug Applications

Wed, 27 Aug 2025

US FDA Approves New Biktarvy Indication For People With HIV Who Are Treatment Experienced And Restarting Antiretroviral Treatment

Drugs.com - New Drug Approvals

Wed, 30 Jul 2025

FDA Approves Anzupgo (delgocitinib) Cream for the Treatment of Chronic Hand Eczema

Drugs.com - New Drug Approvals

Wed, 23 Jul 2025

FDA Approves Khindivi (hydrocortisone) Oral Solution for Pediatric Patients with Adrenocortical Insufficiency

Drugs.com - New Drug Approvals

Wed, 28 May 2025

FDA Approves Tryptyr (acoltremon) Ophthalmic Solution for the Treatment of Dry Eye Disease

Drugs.com - New Drug Approvals

Wed, 28 May 2025

Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

Drugs.com - New Drug Applications

Tue, 27 May 2025

FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia

Drugs.com - New Drug Applications

Wed, 14 May 2025

FDA Approves Imaavy (nipocalimab-aahu) for the Treatment of Generalized Myasthenia Gravis (gMG)

Drugs.com - New Drug Approvals

Wed, 30 Apr 2025